 
        
        
        YHO-13177是一种选择性和强效的 BCRP 抑制剂,IC50 为 10 nM,可增强 SN-38 在表达 BCRP 的癌细胞中的细胞毒性,但对 MDR1 介导的紫杉醇耐药性无影响。
 
                                 
                                
                            

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + | 
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
 
                        
                    
| 描述 | Breast cancer resistance protein (BCRP) is a member of the ATP-binding cassette (ABC) transporter superfamily that regulates drug resistance. YHO-13177 is a novel acrylonitrile derivative that has been shown to reverse BCRP-mediated drug resistance both in vitro and in vivo. In BCRP-transduced HCT116 cells, treatment with YHO-13177 at 0.01-1 μM reversed the drug resistance to BCRP substrates (SN-38, topotecan, and mitoxantrone) in a dose-dependent manner, while it showed no effect on the drug sensitivity of parental HCT116 cells expressing no BCRP. YHO-13177 at the concentrations of 0.01-1 μM also reversed the drug resistance in A549 cells with BCRP-mediated acquired resistance to SN-38. The cytotoxicity of SN-38 in cells that intrinsically express BCRP (RPMI-8226, NCI-H23, NCI-H460, and AsPC-1 cell lines) was significantly potentiated by YHO-13177 at 0.01-1 μM. Treatment with YHO-13177 (0.1 to 10 μM) significantly induced the intracellular accumulation of Hoechst 33342 in both A549/SN4 and HCT116/BCRP cells. YHO-13177 from 0.01-1 μM partially suppressed the expression of BCRP protein in both A549/SN4 and HCT116/BCRP cells without affecting the mRNA expression of BCRP. In mice inoculated with BCRP-transduced murine leukemia P388 cells, the combined treatment of irinotecan (i.v., 45 mg/kg) and YHO-13351 (p.o., 50, 100, or 200 mg/kg), a prodrug of YHO-13177, significantly enhanced the survival time of mice in a dose-dependent manner[2]. | 
| 作用机制 | YHO-13177 is a novel acrylonitrile derivative that reverses the drug resistance and enhances the cytotoxicity of anticancer drugs in BCRP-expressing cancer cells and xenografts by inhibiting the drug transport function and the posttranscriptional expression of BCRP. | 
| Concentration | Treated Time | Description | References | |
| Mouse small intestinal 3D organoids | 20 μM | 20, 40, 60, 80, 100 minutes | To verify the inhibitory effect of YHO-13177 on BCRP-mediated Hoechst 33342 transport, results showed that YHO-13177 significantly inhibited BCRP-mediated Hoechst 33342 transport | Drug Deliv. 2017 Nov;24(1):1453-1459. | 
| 计算器 | ||||
| 存储液制备 |  | 1mg | 5mg | 10mg | 
| 1 mM 5 mM 10 mM | 2.70mL 0.54mL 0.27mL | 13.50mL 2.70mL 1.35mL | 26.99mL 5.40mL 2.70mL | |
| CAS号 | 912287-56-0 | 
| 分子式 | C20H22N2O3S | 
| 分子量 | 370.47 | 
| SMILES Code | N#C/C(C1=CC=C(OC)C(OC)=C1)=C\C2=CC=C(N3CCC(O)CC3)S2 | 
| MDL No. | MFCD28900680 | 
| 别名 | |
| 运输 | 蓝冰 | 
| InChI Key | NOGGBVNCVONHHC-RVDMUPIBSA-N | 
| Pubchem ID | 16757522 | 
| 存储条件 | In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, sealed in dry, 2-8°C | 
| 溶解方案 | DMSO: 35 mg/mL(94.48 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 
 | 
 沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1
			沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1